Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Deferred Taxes (2016 - 2025)

Integra Lifesciences Holdings' Deferred Taxes history spans 17 years, with the latest figure at -$10.9 million for Q4 2025.

  • For Q4 2025, Deferred Taxes fell 56.67% year-over-year to -$10.9 million; the TTM value through Dec 2025 reached -$66.3 million, down 219.64%, while the annual FY2025 figure was -$66.3 million, 219.64% down from the prior year.
  • Deferred Taxes for Q4 2025 was -$10.9 million at Integra Lifesciences Holdings, down from -$8.7 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $10.7 million in Q4 2021 and bottomed at -$44.8 million in Q2 2025.
  • The 5-year median for Deferred Taxes is -$3.3 million (2021), against an average of -$5.3 million.
  • The largest annual shift saw Deferred Taxes skyrocketed 387.2% in 2022 before it plummeted 2331.18% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at $10.7 million in 2021, then plummeted by 156.07% to -$6.0 million in 2022, then plummeted by 146.48% to -$14.8 million in 2023, then surged by 52.94% to -$7.0 million in 2024, then tumbled by 56.67% to -$10.9 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Deferred Taxes are -$10.9 million (Q4 2025), -$8.7 million (Q3 2025), and -$44.8 million (Q2 2025).